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Introduction 
 
Tobacco smoking results in an estimated 480,000 deaths and 
$300 billion in healthcare costs in the U.S., annually.1 Smoking 
kills more people than alcohol, AIDS, car accidents, illegal drugs, 
and homicide/suicide combined.  More than 16 million people 
currently suffer smoking related illness.  Smoking is the leading 
cause of both coronary heart disease and cancer, which together 
comprise the two leading causes of mortality.  Though the past 50 
years has brought about significant public health improvements in 
tobacco control, the prevalence of smoking has declined only 
incrementally in recent years, with current national prevalence at 
17%.2  There are clear needs to improve smoking cessation at the 
individual level and, perhaps more importantly, at the population 
level.     
 The basic principles of promoting smoking cessation on a 
population-wide basis are rooted in the following formula3: 
 
Impact = PQA  x PQuit Method x Psuccess/method 
 
where PQA is the probability of making a quit attempt (QA), PQuit 
Method is the probability of using a specific quit method for that 
attempt, and Psuccess/method is the probability of success for that 
method.  The goal of any population-based smoking cessation 
effort is to increase the probabilities of making a quit attempt, 
using evidence-based methods, and improving upon those 
methods.  Most clinical efforts focus on the latter; i.e., developing 
new and improved cessation techniques (behavioral or 
pharmacotherapy).  There are a number of evidence-based 
treatment options for smoking cessation.  USPHS clinical 
practice guidelines4 and other meta-analyses5-7 provide systematic 
reviews of empirically supported methods for treating tobacco 
dependence. Chief among these recommendations are that 1) all 
tobacco users should be offered brief advice to assist them with 
quitting, and 2) unless medically contraindicated, all smokers 
should be offered pharmacotherapy. Consistent with the latter, the 
most widely used medication is nicotine replacement therapy 
(NRT): patch, gum, lozenge, nasal spray, and inhaler. Among 
these options, only patch, gum, and lozenge are available over the 
counter, and thus offer greatest potential for translational 
effectiveness.  NRT medications work to alleviate withdrawal 
and craving that are so common when quitting,8,9 thereby 
increasing the likelihood of long-term success.  All are safe, and, 
as a general rule, will double one’s probability of achieving 
abstinence.7  Other cessation medications exist (varenicline and 
bupropion), each with a substantial evidence base,10-14 but are 
prescription based and offer reduced availability and access.   
 Another approach, just as reasonable, is to focus on the former 
inputs in the above equation; i.e., getting more smokers to try to 
quit, and moving them to use the best known methods.   This has 
been a greater challenge.  The incidence rate of quit attempts (i.e., 
percent of smokers who make a quit attempt each year) has not 
changed much in over a decade.15  Among those who do make a 
quit attempt, use of pharmacotherapy is low.16-18  Most smokers 
attempt to quit on their own, which is the least successful way to 
quit.4,19  In fact, epidemiological data as applied to the above 
formula show that unassisted quitting (i.e., “cold turkey”) has the 
largest population impact overall – not because it so efficacious 
(it has a very low Psuccess/method), but because it is so predominant 
(very high PQuit Method).  Tobacco control efforts should shift this 
balance, focusing on an increase of quit attempts using evidence-
based treatments.       
 There are a number of well-established methods to induce 
quitting among smokers, including both policy-based (e.g., 
taxation, smokefree legislation) and clinical.  Examples of the 
latter include physician advice and motivational interviewing, 
both of which have substantial evidentiary basis.20-22  However, 
such strategies often rely on persuasive messaging, eliciting 
reasons for quitting and obstacles to change.  While effective for 
some, many clinicians and smokers can feel frustrated by verbal 
techniques, and additional options are needed.  Our group has 
been examining concrete, behavioral, and pragmatic strategies to 
promote quit attempts and use of evidence-based treatment, 
particularly among those who express unwillingness to do so.  
Our view of pragmatic strategies is similar to others,23-25 with an 
emphasis on methods that are brief, feasible, scaleable, easily 
understood (by both provider and smoker), and easily 
disseminated.  We believe such novel strategies are needed to 
address separate elements of the equation above, with a particular 
focus on increasing the both incidence of quit attempts and usage 
of evidence-based treatment.  Below we document a series of 
studies along this theme. 
 
Smoking Reduction 
 
Under the premise that reduction might facilitate quit attempts, 
we conducted a nationwide, randomized clinical trial (N=616) in 
which we randomized smokers who did not want to quit into one 
of three groups: 1) NRT-assisted reduction counseling, 2) time-
matched motivational advice, or 3) no treatment control.26  Our 
trial was an explicit test of whether reduced smoking per se 
would serve as a catalyst to cessation among smokers not wanting 
to quit, not to be confused with the process of gradual quitting 
among smokers with firm quit plans.  Participants were recruited 
through market research panels and all interventions were 
administered via phone and mail.  Smokers in the reduction group 
were guided through a structured protocol to reduce smoking by 
50%, after which they were prompted with firm advice to quit 
entirely.  The rationale for reduction was simple – that it would 
provide concrete evidence of success and control over smoking, 
however incremental, and that this would bolster confidence and 
strengthen motivation to quit.  Outcomes were tracked 
prospectively for six months, and results supported the main 
hypothesis: more smokers in the reduction (43%; RR = 2.8; 95% 
CI: 1.9 – 4.0) and motivational (51%; RR = 3.3; 95% CI: 2.3 – 
4.7) conditions made a 24-hour quit attempt over 6 months than 
smokers in the no treatment condition (16%) but the two active 
conditions did not differ.  Similarly, 18% of participants within 
the reduction group (RR = 4.0; 95% CI: 2.0 – 8.1), 23% of the 
motivational advice group (RR = 5.4; 95% CI: 2.7 – 10.7) and 
4% of the no treatment group were abstinent (7-day point 
prevalence) at six months (see Figure 1) and again the two active 
treatments did not differ.26  Thus, reduction facilitated quitting 
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and was as effective as motivational advice, with both options 
easily disseminable among clinicians.  Subsequent literature 
reviews of smoking reduction, both within our group27,28 and by 
others29-32 provided further support for smoking reduction as a 
behavioral strategy to induce quit behavior.  While our trial 
results were encouraging for smoking reduction, they were 
strongly confounded by NRT use.  It was unclear whether the 
effect on cessation was driven by a) the behavioral act of cutting 
down on cigarettes per day or b) the experiential exercise of using 
medication.  Some evidence within our trial suggested the latter.  
We subsequently isolated this effect through a series of NRT 
sampling studies described further below. 
   
Usage, Attitudes, and Perceptions of NRT 
 
We separately conducted two complementary studies that 
documented attitudes and misperceptions of cessation 
medication. The first was a qualitative study of perceptions of 
NRT specifically33 and highlighted enduring misperceptions 
about the rationale, development, safety, and efficacy of NRT, all 
of which likely undermine usage.  This study also suggested 
possible racial/ethnic differences in how cessation medications 
are viewed, which may in part explain particularly low rates of 
medication use among African American smokers.  Our second 
study of attitudes towards cessation pharmacotherapy was a 
phone-based cross-sectional survey of South Carolina smokers.34 
Attitudes towards pharmacotherapy among current smokers 
(N=697) are presented in Table 1, and show modest endorsement 
of treatment in general, or cessation medications in particular, 
and that such barriers may differ by race.  From these studies, we 
believed that greater effort was needed to educate smokers about 
cessation medication (NRT in particular), and that there was no 
better way to learn about it than to use it.    
 
NRT Sampling: Study 1 
 
Our experiences above led us to investigate whether sampling of 
cessation medication, and NRT specifically, would facilitate quit 
attempts and cessation among smokers not yet ready to quit.  
There are several mechanisms by which sampling could promote 
downstream changes in smoking behavior.  One is through 
improved self-efficacy. As smokers gain confidence in 
controlling smoking, they may be more likely to believe that total 
abstinence is possible. Second, medication sampling might 
heighten motivation. Whereas abrupt quitting is often daunting, 
gradual exposure to cessation, particularly when that experience 
is made easier through NRT, might remove some of the perceived 
barriers to quitting.  Third, simply trying a medication without 
any firm commitment for long-term use may dispel 
misperceptions and increase familiarization, directly addressing 
barriers as suggested in Table 1.  Finally, sampling may increase 
autonomy, promoting self-control over smoking and the process 
of quitting.  Collectively, these principles are wholly consistent 
with self-determination theory;35,36 i.e., the rationale that smokers 
will be more successful if they are invested in, knowledgeable of, 
and motivated for quitting if they decide for themselves the goals, 
pace, and strategies for changing tobacco use.  NRT give-away 
programs are common within quitlines, with demonstrated 
success.37-39 However, quitlines are underutilized40 and by 
definition generally reach smokers who are actively seeking out 
and receptive of treatment.  Our goal was to take these same 
principles and apply them more broadly.      
 We first conducted a randomized clinical trial (N=849) testing 
the concept of NRT sampling to induce cessation behavior among 
smokers unmotivated to quit.41,42  Smokers were again recruited 
nationally via online channels for a phone-based intervention 
trial, and were assessed for six months. Treatment consisted 
either of 1) NRT sampling, within the context of a practice quit 
attempt (PQA), or 2) PQA alone. The PQA intervention was a 
behavioral exercise, within which smokers could (or could not) 
sample nicotine replacement. The PQA was designed to increase 
motivation, confidence, and coping skills. The added value of 
NRT samples (nicotine lozenges) was hypothesized to familiarize 
smokers with NRT, promote wider acceptance of it, and 
ultimately to enhance motivation and confidence even further.  
Though participants were provided with a brief overview of 
medication and supporting rationale, a repeated theme was on 
self-determined use: to use NRT “if and how you wish.”  Uptake 
of NRT during the sampling period was strong: 73% of smokers 
used the product, for an average of 9 days. Cessation outcomes 
were very promising, with significant increases in quit attempts 
and some measures of abstinence (Figure 2).  Follow-up 
mediational analyses43 revealed that the added influence of NRT 
sampling worked largely as intended, through hypothesized 
mechanisms above. 
 
NRT Sampling: Study 2 
 
The trial above was based on unmotivated smokers only.  We 
next completed a separate semi-randomized pilot trial of smokers 
across three groups (N=157), testing: smokers motivated to quit, 
given 2-week samples of both nicotine patch and lozenge 
(Motivated/NRT), vs. unmotivated smokers, either randomized to 
 
      Table 1.  Attitudes towards Cessation Medications: Current Smokers1 
 African American Caucasian-American p 
How well do medications work to help smokers quit? 42% 50% .03 
How concerned are you about medication safety? 51% 46% .17 
How concerned are you that you might get addicted? 30% 23% .03 
How concerned are you about cost? 55% 60% .22 
How much treatment of any kind do you need to quit? 50% 60% .008 
How much do you need medication to help you quit? 44% 51% .07 
 
 
Figure 1.  Incidence of quit attempts and cessation 
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the same treatment (Unmotivated/NRT), or not 
(Unmotivated/NoTx).44 The rationale for combination NRT was 
fourfold.  First, a number of studies demonstrate their efficacy 
when used singularly.4  Second, they are both over the counter, 
increasing their dissemination appeal within in various 
populations.  Third, whereas the patch provides a steady dose of 
nicotine throughout the day, the lozenge is used ad libitum and 
provides acute nicotine administration.  These two mechanisms 
might appeal to smokers differently. Fourth, two trials45,46 and a 
separate review within our group47 have shown that combined use 
of patch + lozenge is superior over placebo and single NRT 
products.  We expected superior outcomes (higher incidence of 
quit attempts and cessation) within Motivated/NRT Group, since 
they expressed motivation to quit and were given tools to do so, 
and we anticipated inferior outcomes within Unmotivated/NoTx 
Group, since they had neither.  The main focus was on the 
Unmotivated/NRT Group, who shared commonality with first 
(active sampling of medication) and last group (unwillingness to 
quit).  Rates of incidence for quit attempts through three months 
were ordinal:44 62% vs. 32% vs. 16% (Figure 3), while rates of 
abstinence (7-day point prevalence at final follow-up) were 
generally comparable between Motivated/NRT and 
Unmotivated/NRT Groups (17% vs. 15%), a 3-fold increase over 
Unmotivated/NoTx Group (5%; all pairwise comparisons not 
statistically significant but still clinically meaningful).44  Our 
results provide further support for the concept of sampling 
medication as a method to induce quitting.  Results also indicate 
that while initial motivation to quit enhances outcomes 
(Motivated/NRT vs. Unmotivated/NRT), it is not a necessary 
precursor to success (Unmotivated/NRT vs. Unmotivated/NoTx).   
 
NRT Sampling: Study 3 
 
The collective evidence above suggests a role for medication 
sampling to promote quit attempts and abstinence among 
smokers.  Overall effect sizes are moderate, but when applied in a 
larger context, the population impact could be large.  Our third 
trial is a cluster randomized trial of NRT sampling within real-
world, primary care settings (N=1160; 20 clinics).  The study is 
inclusive of all smokers regardless of motivation to quit, which 
may or may not become a potential moderator of treatment 
outcome.  NRT sampling is particularly well suited to any 
number of medical settings, much like within a dental setting 
where patients are given product samples at the end of each visit, 
in that it is brief (i.e. incurs no extra demands on a busy provider 
or staff) and has intuitive face validity.  As throughout above, 
messaging emphasizes self-determined use: ~”as your provider, 
we think these medications can help, even if you’re not ready to 
quit.  Try them and see for yourself.”  Outcomes will be assessed 
through six months, and are focused across three levels: a) 
individual smoker outcomes, as defined above (also: further use 
of medication, use of behavioral support including quitlines), b) 
provider outcomes (e.g., satisfaction and confidence in cessation 
counseling), and c) aggregate clinic outcomes (e.g., screening and 
treatment of all smokers, including those not within study).  The 
trial is ongoing and expected end date is late 2017. 
 
Role of Alternative Tobacco Products to Promote 
Quitting 
 
The proliferation of alternative tobacco products gives rise to 
parallel research questions along this same theme: what effect 
will they have on quitting?  The market of potentially safer 
products has vastly expanded in recent years, and though there is 
wide variation within this market, most new products are non-
combustible and thus offer reduced harm to the individual user.  
For example, low nitrosamine smokeless tobacco (LNSLT) has 
been popular in Scandinavian countries for years, where rates of 
lung cancer have significantly decreased.48-50  LNSLT, also 
known as snus, differs from traditional smokeless tobacco in that 
it is pouched, spitless, flavored, and marketed directly to cigarette 
smokers as a substitute product.  As such, whether and how snus 
changes smoking behavior is a compelling public health question.  
Snus could conceivably help smokers quit cigarettes, or, 
alternatively, it could maintain dependence, allowing them to 
circumvent smoking restrictions, engage in long term dual use, 
and thus undermine smoking cessation.  Only a few randomized 
clinical trials of snus exist,51-54 and all are cessation-focused, i.e., 
recruiting smokers wanting to quit and explicitly testing snus as a 
strategy to do so.  These studies generally show positive effects 
on snus on cessation.  However, these studies do not address the 
naturalistic population impact of snus on smoking behavior, and 
this remains an important gap in the literature. 
 We first conducted two pilot studies, both randomized tests of 
smokeless tobacco55,56 which generally showed reductions in 
smoking and increases in motivation to quit compared to control  
groups.  Next, following much of the methods of the NRT 
sampling studies above, our group conducted what we believe is 
the largest (N=1236), longest (1-year), and most direct 
Figure 2. Rates of A) any quit attempt (QA), B) 24hr quit 
attempt, C) floating abstinence (7 days, no smoking, at any 
point in study), and D) 7-day point prevalence (PP) 
abstinence at Week 26, among smokers engaged in a practice 
quit attempt (PQA), with or without NRT samples.  
 
 
Figure 3.   Rates of 24-hr Quit Attempts and Point Prevalence 
Abstinence among groups of smokers who: A) endorsed 
motivation to quit and received samples of nicotine patch and 
lozenge (Motivated/NRT), B) did not endorse motivation to 
quit but got same treatment (Unmotivated/NRT), and c) did 
not endorse motivation to quit and got no treatment 
(Unmotivated/NoTx). 
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(randomized design) study of snus among U.S. smokers.  
Smokers unmotivated to quit, recruited nationwide, were 
provided a six-week sample of snus vs. not, followed by periodic 
assessment for an additional 12 months.  Sampling of snus was 
entirely self-determined.  The primary outcome was incidence 
and duration of quit attempts, and secondary outcomes were point 
prevalence abstinence from cigarette smoking, at 6 and 12 
months, smoking reduction, and associated measures of quitting; 
no support from the tobacco industry was provided.  The trial is 
recently completed and results are forthcoming elsewhere.  The 
results will add to the literature on snus and will provide an 
important contribution to the clinical and regulatory debate as to 
how these products fit within the landscape of tobacco control.       
 More recently, the exponential growth of electronic (e-) 
cigarettes has dramatically shifted the focus of alternative 
products.  Models of e-cigarettes span a wide spectrum, from 
disposable cartridges to highly sophisticated tank systems 
including ones that allow the user to control the amount, dose, 
and power of nicotine delivery.  The basic operation of any e-
cigarette involves the heating and vaporization of nicotine; there 
is no combustion.  E-cigarettes attenuate craving to varying 
degree,57 but this is likely dependent upon type of e-cigarette 
product. Like LNSLT, growing evidence58,59 suggests that e-
cigarettes are safer than conventional cigarettes, delivering 
significantly reduced levels of tobacco-specific nitrosamines; i.e., 
primary class of carcinogens within tobacco.  How e-cigarettes 
alter behavior is unclear.  Only three randomized studies exist.60-
62  All come from abroad, and most are cessation-driven (use of 
e-cigarettes to help smokers quit) and not naturalistic.  Results are 
generally supportive that use of e-cigarettes might facilitate 
quitting, which supports some but not all indirect (i.e., non-
randomized, cross-sectional) evidence elsewhere.63-68  Our group 
is now testing e-cigarettes much like we have done for NRT and 
snus sampling studies above: using randomized designs but still 
focusing on naturalistic, self-determined use.  One placebo-
controlled crossover study is recently completed, another 
prospective study is ongoing, and a larger trial is planned.  In 
time we believe these studies will guide understanding of the 
clinical and population impact of electronic nicotine delivery 
systems.    
 
Conclusion 
 
Many smokers remain unable or unwilling to quit.  Among those 
who try to quit, unaided attempts are the most common, yet least 
effective strategy.  Many evidence-based treatments, including 
those that are the most accessible, remain under-used by smokers.  
Promoting active treatment to all smokers, even if they do not 
wish to quit, offers a strong opportunity to increase cessation at 
the population level.  Increasing both the incidence of quit 
attempts and the use of evidence-based treatment for those 
attempts offers strong potential to move smokers away from 
unproven (unassisted) ways of quitting and thus offers an 
opportunity to dramatically increase the impact of smoking 
cessation.  Allowing smokers to sample cessation medication on 
their own terms increases quit attempts and quitting, often among 
those resistant to do so.  Sampling of medication, particularly 
NRT, is easy to disseminate within any number of real-world 
medical settings, reaching large numbers of smokers.  The role of 
alternative tobacco products to promote quitting is less clear.  
There is strong need for large scale, randomized, but still 
naturalistic studies of products, particularly e-cigarettes, which 
may or may not promote quit attempts and cessation.  Dr. 
Carpenter is grateful to the South Carolina Academy of Science 
for acknowledgment of his work, and is deeply indebted to the 
many individuals who have collaborated and supported this 
research.  
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